Corporate Profile

Company Overview

MMJ PhytoTech Limited is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.

The newly merged entity MMJ-PhytoTech now comprises of the following operating units:


United Greeneries is the Canadian based subsidiary of MMJ PhytoTech. It currently owns two state-of-the-art medical grade cannabis cultivation facilities, the Duncan Facility and the Lucky Lake Facility, with a combined footprint of 78,000ft².

The Duncan Facility and Laboratory is a 16,000ft² building with a level-8 vault, 3 bays and close to 10,000ft² of cultivation area. The facility is completely built out and is located on Vancouver Island in Duncan, British Columbia. Duncan has an integrated fully compliant QA/QC (Quality Assurance and Quality Control) laboratory for internal testing as well as third party testing services as required by Health Canada. The Duncan Facility will be able to produce up to 700kg of Medical Grade Cannabis per annum once granted an MMPR (Marijuana for Medical Purposes Regulation) production license, which the Company expects to occur in the second half of 2015.

AgriChem Analytical is part of the United Greeneries operation. It provides state-of-the-art biochemical quality control testing and Cannabinoid analytics, as required under the Canadian MMPR (Marijuana for Medical Purposes Regulation). AgriChem Analytical is directly integrated with United Greeneries’ Duncan cultivation facility. These services play an essential role in furthering Cannabinoid drug development and continuous compliance with MMPR quality requirements.

Satipharm is the Swiss subsidiary of MMJ PhytoTech developing cannabis based pharmaceutical, nutraceutical and cosmetic products for a variety of conditions. Satipharm, together with its cannabis extraction manufacturing partners, has developed a proprietary gastro-resistant Cannabidiol (CBD) pill. The pill will be legally sold as a dietary supplement over the counter in Europe.

PhytoTech Therapeutics is the Israeli based subsidiary of MMJ PhytoTech focusing on the development of drug-products for administering cannabinoids to treat various medical conditions. The company has entered into an exclusive research and licensing agreement with Yissum Research Development Company, the prestigious research development and technology transfer company of the Hebrew University of Jerusalem.  

PhytoTech Therapeutics is developing a number of products including an oral capsule and buccal patch  containing a combination of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for treating various clinical indications. The first product aimed to enter shortly into clinical studies is an oral capsule for the treatment of pain and spasticity in Multiple Sclerosis patients.

SUBSCRIBE NOW for updates from Managing Director, BOAZ WACHTEL